Prelude Therapeutics IncPRLD
Price$3.79Intrinsic value$3.913% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $22.4M+220.3% YoYTTM through 30 Jun 2026
Net Income -$60.5MTTM through 30 Jun 2026
Free Cash Flow -$33.3MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-293.5%
Operating Margin-309.5%
Net Margin-269.8%

Returns

-129.3%ROE
-65.0%ROA

Balance Sheet Health

Debt / Equity0.29x
Current Ratio2.03x
Net Debt-$63.8Mnet cash position
Cash & Equivalents$26.3M

Quality Metrics

Altman Z-Score-1.38
Piotroski F-Score4 / 9
FCF Margin-148.3%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'24'25
FY2025: $12.1M
Diluted EPS-$0.73TTM
'21'22'23'24'25
FY2025: $-1.29

Dividend

No dividend

Capital Allocation

Capex Intensity0.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.